Familiar Renal Disease, Epidemiology and Genetics in Niteroi/Rio de Janeiro (REGENT)

September 19, 2020 updated by: Jorge R Almeida, MD, Universidade Federal Fluminense

The REGENT Study: Familiar Renal Disease, Epidemiology and Genetics in Niteroi/Rio de Janeiro

The REGENT study (Familiar Renal Disease, Epidemiology and Genetics in Niteroi/Rio de Janeiro) is a epidemiological study that try to identify and clinically describe questions about genetic renal diseases in a southeast Brazilian population undergoing renal replacement therapy.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

In Brazil, several kidney diseases have unknown etiological diagnosis, among them, hereditary renal diseases. The lack of technical-scientific knowledge and patients' access to the health service hinder the correct diagnosis, so that hundreds of patients with chronic kidney disease (CKD) are unaware of the origin of their kidney problems. The objective of this REGENT study (Renal epidemiology and genetics in Niteroi) is to identify and characterize the cases of possible inheritance of CKD in patients undergoing dialysis or kidney transplant treatment in the metropolitan region II of the state of Rio de Janeiro. In this metropolitan region, based in the city of Niteroi, there are 10 hemodialysis clinics accounting for approximately 1500 - 1800 patients. There is a central Hospital that works as an official reference center for all those CKD patients (Hospital Universitario Antonio Pedro). This hospital belongs to the Universidade Federal Fluminense, an academic research institution, where this project will be executed. There is also a kidney transplant unit working at the Hospital Universitario Antonio Pedro. Interviews, sociodemographic and clinical data collection will be performed in patients with CKD from these centers. The interview contains questions about family CKD: Does any family member undergo hemodialysis or peritoneal dialysis? Does any family member do/did conservative treatment for CKD? Has any family member had a kidney transplant? Has any family member died due to chronic kidney disease? In cases of any affirmative answer to one of the above questions, patients will be classified as a "family index case". The cases of familial kidney disease caused by diabetes, and polycystic kidney disease will be excluded. So, the remaining cases will be considered as "index cases" to be more described and characterized. In this way, an affirmative response to the survey will create a group of familial CKD, and it will allow us to identify them as a suspected genetic kidney disease. These patients will be analyzed as a group, and clinical histories and blood tests to genetic renal diseases will also be performed, when possible, depending on the availability. From these identified index cases, we will try to create familiar clinical description of each individual in every family. A new outpatient section is being created at the Hospital Universitario Antonio Pedro to take multidisciplinary care of the relatives and entire families in a special type of family primary care.

Study Type

Observational

Enrollment (Actual)

1308

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • RIO DE Janeiro
      • Niteroi, RIO DE Janeiro, Brazil, 24033900
        • Universidade Federal Fluminense

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

1 year to 80 years (Child, Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

The population to be studied will be formed by southeast Brazilians that are on renal replacement therapy as dialysis or kidney transplantation. Such patients with renal diseases will answer a questionnaire about familial involvement. Some of them will be characterized as a familial index case of not yet determined genetic kidney disease.

Description

Inclusion Criteria:

  • Brazilian patients underwent any type of renal replacement therapy, dialysis or kidney transplantation living in the area of Niteroi/Rio de Janeiro.
  • Relatives among the familial people of the index cases.

Exclusion Criteria:

  • Diabetic Nephropathy
  • Non-familial cases of known Glomerulonephritis
  • Refuse in participating of interview and blood collection to genetic tests

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Family-Based
  • Time Perspectives: Prospective

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
CKD patients

'blood collection'

Patients with chronic kidney disease in renal replacement therapy living in the sanitary administrative region of Niteroi/Rio de Janeiro. They will be interviewed about past history of familiar renal disease. They will have blood functional renal biochemistry analysed.

They will have blood tested to renal genetic diseases
Renal Familiar Disease
'blood collection' They will have blood tested to renal genetic diseases
They will have blood tested to renal genetic diseases

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Frequency and numbers of patients with renal familial diseases that are on renal replacement therapy in southeast Brazil.
Time Frame: The familial epidemiological results will be ready up to 24 months form the start of the study.
We will proceed a clinical interview using a questionnaire focused on the family history, among each Brazilian patients from dialysis or transplant center from the region of Niteroi/Rio de Janeiro. Patients with a positive history of familial disease will be included as a "case of familial renal disease". The results of the interviews will be analysed to create a report about incidence and prevalence of genetic renal disease among the southeast Brazilian people. At the same time we are creating a genetic reservoir to characterization of renal diseases in southeast of Brazil and we are also creating the basis to a cohort study based these families, through a new recently created outpatient unit to take care of familial renal diseases to follow all these involved renal families.
The familial epidemiological results will be ready up to 24 months form the start of the study.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Frequency of uromodulin and APOL-1 mutation in southeast Brazilian patients underwent renal replacement therapy
Time Frame: From the time to DNA extraction, by using molecular studies, the DNA samples of each index cases will be analyised to uromodulin and APOL1, up to 48 months.
A complete mutation analysis, with identification of polimorphism SNPs to uromodulin and APOL-1 will be place as an initial specific protocol by using extracted DNA from the familial index cases.
From the time to DNA extraction, by using molecular studies, the DNA samples of each index cases will be analyised to uromodulin and APOL1, up to 48 months.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Jorge R Almeida, MD, PhD, Universidade Federal Fluminense

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 20, 2017

Primary Completion (Actual)

December 20, 2019

Study Completion (Actual)

September 19, 2020

Study Registration Dates

First Submitted

March 20, 2017

First Submitted That Met QC Criteria

April 10, 2017

First Posted (Actual)

April 14, 2017

Study Record Updates

Last Update Posted (Actual)

September 22, 2020

Last Update Submitted That Met QC Criteria

September 19, 2020

Last Verified

August 1, 2019

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • REGENT study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

Undecided

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Kidney Diseases

Clinical Trials on blood collection

Subscribe